Navigation Links
Phase 1 / 2 Clinical Trial Results of KRX-0401 (Perifosine) Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Published in the Journal of Clinical Oncology
Date:10/13/2011

h a median PFS of 8.8 months in the bortezomib-relapsed population.  Median overall survival (OS) was 25 months.  Therapy was generally well-tolerated; toxicities, including gastrointestinal side-effects and fatigue, proved manageable.  No treatment-related mortality was seen.  

The investigators concluded that the combination of perifosine and bortezomib is active and well-tolerated in heavily pre-treated MM patients previously treated with bortezomib, and that the survival data in this study is encouraging, even in patients previously exposed to, and refractory to, bortezomib, as well as prior immunomodulatory drugs.

Data from this study was previously presented at the 2009 American Society of Hematology (ASH) conference.

A copy of the article featured in the current online edition of the Journal of Clinical Oncology can be obtained at http://jco.ascopubs.org/content/early/2011/10/04/JCO.2010.33.9788.full.pdf+html

KRX-0401 (perifosine) is in-licensed by Keryx from Aeterna Zentaris Inc. (NASDAQ: AEZS) in the United States, Canada and Mexico.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colo
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Telik Announces Initiation of a Phase 2b Clinical Trial of Telintra® (Ezatiostat HCL) in Patients With Low to Intermediate-1 Risk Non-Deletion (5q) Myelodysplastic Syndrome
2. Merrimack Pharmaceuticals Initiates Enrollment in a Neoadjuvant Phase 2 Study of MM-121 with Paclitaxel in HER2-negative Breast Cancer Patients
3. Omeros Announces First Patients Treated in Phase 3 Clinical Program Evaluating OMS302
4. Hepatitis C Phase 2A Trial Positive Results
5. Daval International Announces Positive Phase II Results for AIMSPRO® as a Monotherapy in Established Diffuse Cutaneous Systemic Sclerosis (Scleroderma)
6. Journal of Clinical Oncology Publishes Phase 2 Clinical Trial Results of KRX-0401 (Perifosine) Plus Capecitabine in Patients with Metastatic Colorectal Cancer
7. GeoVax Phase 2a Clinical Trial Completes Enrollment
8. Telik Announces Publication in the Journal Cancer of a Phase 2 Randomized Multicenter Study of Two Extended Dosing Schedules of Oral Ezatiostat in Low to Intermediate-1 Risk Myelodysplastic Syndrome
9. Vitala™ Pouchless Continence Control Device Shown to be Safe and Effective for up to 12 Hours in Phase 3 Clinical Trial
10. Visual Healthcare to Supply Enabling Technology for Home Care Consortium Software and Support Revenues to Reach $17 M in Phase One
11. Adamas Pharmaceuticals Initiates a Phase 2/3 Clinical Study of ADS-5102 for Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 19, 2014  Newport Corporation (NASDAQ: ... has joined the company,s Board of Directors.  Dr. ... a director of Evans Analytical Group, a leading ... analytical services to companies in a wide range ... Evans Analytical Group, Dr. Kadia spent nine years ...
(Date:12/19/2014)... 2014 Breckenridge Pharmaceutical, Inc. announced today that ... Laboratories Pvt. Ltd. ( Hyderabad, India ) ... new ANDAs.  Under the terms of the agreement, MSN ... Breckenridge for the U.S. market, and Breckenridge will market ... MSN have agreed to develop an oral antibiotic with ...
(Date:12/19/2014)... , Dec. 19, 2014 In ... research and marketing communication tools are essential for ... competitive – consequently consumers, desires, preferences, and unmet ... environment, market research groups across all industries are ... communication tools. However, the adoption of new market ...
Breaking Medicine Technology:Siddhartha Kadia, Ph.D. Joins Board of Directors of Newport Corporation 2Breckenridge Pharmaceutical signs Multi-Product Generic Agreement with MSN Laboratories Pvt. Ltd. 2Study Uncovers New Tools and Techniques for Understanding Consumer Decision Making 2
... SKILLMAN, N.J., Feb. 7, 2011 ConvaTec, a world-leading ... and hospital care, today announced the appointment of several ... Nino Pionati has been appointed President, Intercontinental in ... Latin America and Canada. These markets continue to be ...
... 2011 BioSpecifics Technologies Corp. (Nasdaq: BSTC ... first in class collagenase-based products, today announced that its ... "Rights Agreement"), adopted May 14, 2002 and previously amended ... increases the ownership threshold for determining "Acquiring Person" status ...
Cached Medicine Technology:ConvaTec Announces New Appointments to Leadership Team 2
(Date:12/20/2014)... 20, 2014 Today, Balfleet.com, one of ... Christmas Sale, offering 50%-70% off on its Mother ... , The mother of the bride dresses from Balfleet.com ... is 24/7 accessible and takes pride in providing high ... “We are offering great discounts on our mother of ...
(Date:12/19/2014)... It’s very easy to become overwhelmed with the holidays ... the wayside until Christmas and the New Year are over. ... that burning desire to just escape it all and get ... Telluride with a no-fuss, affordable package. Montrose Days Inn will ... and ensure that all accommodations are met. Plus, everyone has ...
(Date:12/19/2014)... Florida (PRWEB) December 19, 2014 Sub Zero ... to sponsor a blood drive Sunday the 28th from 2pm-6pm ... Road & Sawyer Road in Sarasota, FL. , Inquiries regarding ... thank you for participating in the donating process, Sub Zero ... free flash frozen, custom ice cream. , About Sub Zero ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 ... dedicated to developing educational events, tools and resources ... Rouxbe Cooking School , the world’s leading online ... prescription every human being needs: Culinary Rx. As ... cooking course, Culinary Rx, scheduled for debut spring ...
(Date:12/19/2014)... Santa Rosa, CA (PRWEB) December 19, 2014 ... 2x4 and 5x5 SuperClone Rooms. SuperCloset continues to offer ... grow solutions. Pair one of the new SuperClone Rooms ... truly professional, perpetual, and turnkey indoor hydroponic grow room ... cloner in the world, SuperCloset’s SuperPonic SuperCloner 50 ...
Breaking Medicine News(10 mins):Health News:Balfleet.com is Offering 50%-70% Off of its Mother of the Bride Dresses 2Health News:Days Inn Montrose Colorado Delivers Last Minute Holiday Season Ski Getaway Accommodations 2Health News:Shark Tank’s Sub Zero Ice Cream Sponsors Blood Drive 2Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 2Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 3Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 4Health News:SuperCloset Continues to Innovate with New Complete Indoor Grow Room Packages, The SuperClone Rooms are the Newest Addition to the Award Winning SuperRoom Lineup 2
... Massachusetts General Hospital (MGH), together with a coalition of ... world,s largest registry of patients who have had optical ... an intravascular imaging technology that researchers hope will give ... plaques that cause heart attacks and sudden cardiac death. ...
... finds , THURSDAY, March 25 (HealthDay News) -- More than ... said that they drank alcohol in the past month, according ... The analysis of 2006-2008 data from the National Survey on ... rates were as high as 40 percent in some states, ...
... The effectiveness of ordinary surgical masks as opposed to ... H1N1 influenza virus has been the subject of debate. ... issue of Clinical Infectious Diseases, available online ... as effective as respirators in this regard. ...
... ... strategy to treat motor symptoms in rats with a disease designed to mimic Parkinson,s disease. ... San Francisco, CA (Vocus) ... symptoms in rats with a disease designed to mimic Parkinson,s disease., , , , ,The ...
... This press release is available in French . ... a previously hidden channel to attack leukemia and other cancer ... Journal of Biological Chemistry . The findings from the Universit ... way doctors treat cancer patients. "We found a gateway, ...
... survey finds , THURSDAY, March 25 (HealthDay News) ... likely to be chronically offline: they use the Internet ... , The survey, conducted by the Pew Internet & ... published online March 24, found that just 62 percent ...
Cached Medicine News:Health News:Mass. General Hospital to create registry for coronary optical coherence tomography 2Health News:Underage Drinking Soars in U.S. 2Health News:Novel Parkinson's Treatment Strategy Involves Cell Transplantation 2Health News:Novel Parkinson's Treatment Strategy Involves Cell Transplantation 3Health News:Novel Parkinson's Treatment Strategy Involves Cell Transplantation 4Health News:New gateway to treat leukemia and other cancers 2Health News:Chronic Disease Linked to Less Internet Usage 2
... The Evans AFO is designed to ... disorders associated with immobility such as hip ... at the calcaneus. A comfortable Kodel lining ... patient. The anti-rotation bar is easily ...
Provides secure fracture immobilization while allowing for full range of motion at shoulder and elbow...
... MPO® by RCAI provides adjustable static stretch ... conditions such as diminished foot and ankle ... rotation. Medial/lateral straps attached to the sides ... ankle to be controlled, as needed, in ...
... features a completely padded posterior shell ... to provide passive flexion to help ... or Achilles tendonitis. Its neutral ... left or right. A foam ...
Medicine Products: